RVMD Stock Jumps 8% as Analysts Pile In Before November 5 Print

Revolution Medicines gained nearly 8% on Tuesday to close at $196.55, its biggest single-day move in weeks, arriving just 15 days before its November 5 earnings date with analyst conviction at its highest in months.

The Street has been unusually active. Five separate firms have issued or updated views in the past week alone. TD Cowen reiterated Buy with a fresh $250 target on Tuesday. Truist Securities lifted its target to $241 the day before. RBC Capital has raised its target twice in two weeks, most recently to $260. William Blair initiated coverage at Outperform last Thursday. The mean target across the consensus now sits at $257.53, about 31% above the current price. The analyst recommendation differential factor ranks in the 99th percentile of the ORTEX universe, meaning this stock is as unanimously well-liked by the Street as almost any name in the database. The bull case centers on daraxonrasib's FDA approval in pancreatic cancer, physician enthusiasm for its pan-RAS mechanism, and a pipeline with peak sales potential that analysts have estimated above $16 billion. The bear case points to a competitive KRAS landscape, launch execution risk, and the burn rate that comes with funding both commercial rollout and ongoing R&D.

Short positioning has stabilised after the sharp build documented in the October 14 note. Short interest is flat on the week at 6.1% of the free float, essentially unchanged after a 20%-plus jump in the prior period. Cost to borrow has actually eased, falling 27% over the past seven days to 0.46%, a low absolute level. Availability remains extremely loose at roughly 3,200% of short interest, meaning for every share already borrowed there are around 32 more sitting in the lending pool. Bears who built positions over the past two weeks are not being squeezed or squeezed out. The lending market is not adding any mechanical pressure in either direction. Options positioning pulled back slightly from Monday's elevated reading: the put/call ratio is at 0.94, still above its 20-day average of 0.85 but down from 0.97 the previous session and well off the 1.80 52-week high. The hedging demand that spiked earlier in the week has moderated a touch, though it remains above the recent baseline.

Institutional ownership tells a story of broad accumulation. BlackRock added 2.5 million shares in the September quarter to reach 6.4% of shares outstanding. Fidelity added 3.5 million shares over the same period to reach 5.6%. Capital Research and Management entered the register with a fresh 4 million-share position. Janus Henderson and Baker Bros. each crossed the 5% threshold in recent filings. No 13D activist is on the register. All disclosed stakes are passive 13G filings, and the standard caveat applies: positions are as last disclosed and holders can fall below the 5% reporting threshold without filing again. Insider activity over the 90-day window is net negative at around $36.7 million in sales, but every disclosed transaction is under a pre-arranged 10b5-1 plan, which limits the sentiment read. The Chief Development Officer's September 29 sales were all plan-driven.

RVMD rose 4.3% over the week against a median gain of around 2.3% for its closest correlated peers. COGT added 11.2% and PRAX gained 8.7%, so the biotech cohort broadly moved higher. SNDX and ELDN lagged, each falling roughly 3 to 5%. RVMD's move sits in the upper half of the peer group but is not an outlier. The prior two earnings prints both produced positive reactions: the stock gained 4.6% the day after the August 7 result and 2.2% after the August 5 release, with five-day moves of 2.9% and 6.1% respectively. That history is limited but consistent in direction.

ORTEX puts the probability of RVMD joining the Nasdaq-100 at the December 2026 Annual Review at 27%. The stock would need to close above $257.74 to qualify under the index's market-cap band rules, a move of roughly 31% from current levels. If the review proceeds as scheduled, the rank date falls on November 30, with announcement on December 11 and the effective date December 21. At that flow size, index trackers would need to buy an estimated $3.7 billion of stock, equivalent to 9.5 days of normal trading volume. Past additions of a similar profile produced a median gain of 2.1% from announcement to effective date, with 79% of comparable additions moving in the expected direction. The November 5 earnings print is now the first gate: the commercial launch data for Rasonque will either close or widen the gap to that entry line.